MedInTech, a medical robotics startup, has raised a SeriesC round of USD 25.7 million (33.8 billion won). It plans to use the money to broaden its AI robotic endoscope lineup and move from diagnostic endoscopes into higher-value treatment and surgical applications.

Existing investor Atinum Investment and new investor KB Investment co-led the round. Existing investors Smilegate Investment, SL Investment, ICF (Nextrans) and Wooshin Venture Investment joined with follow-on investments. K2 Investment Partners came in as a new investor. The funds were paid in on the 2nd and 13th, and MedInTech plans to close the Series C round with additional funding within the year.
MedInTech previously raised a Series A of USD 6.1 million (8 billion won) in 2022 and a Series B of USD 15.2 million (20 billion won) in 2024. Including the new round, its cumulative funding comes to about USD 47.3 million (62.2 billion won). Since the Series B, the company has been running clinical validation and commercialization of its AI robotic endoscope and building domestic and overseas distribution. The new round provides the funds for a wider product portfolio and next-generation surgical robot development.
Autonomous steering as the core technology
Founded in 2020, MedInTech develops AI robotic endoscopes that combine robotic precision control and artificial intelligence with gastrointestinal endoscopy, a field that has relied on manual operation by clinicians for decades. Its flagship product, INTION S, uses motor-based precision control. In conventional endoscopes, clinicians steer by pulling wires by hand.
The company says its core strength is extending AI from image analysis to controlling the physical movement of a medical device. Existing medical AI has mostly been used to detect lesions in images or support clinical judgment. MedInTech has built autonomous steering technology that turns what the AI recognizes into endoscope movement. This lowers the operating burden on clinicians and can assist with parts of the procedure, such as steering the scope and tracking lesions.
The robot-drive and precision-control technology developed for diagnostic endoscopes can also be applied to therapeutic endoscopes and surgical robots. MedInTech’s growth strategy is to go beyond competing in the existing endoscope market. It aims to combine AI and robotics that support clinicians’ techniques into a medical physical AI platform covering diagnosis, treatment and surgery.
Clinical results and commercialization
In a clinical trial with 178 adults at Seoul National University Hospital, MedInTech confirmed non-inferiority in key maneuverability measures against conventional mechanical endoscopes. The trial also showed reduced physical fatigue and workload for clinicians. The results were published in the international journal Scientific Reports, and the company has since examined the product’s potential clinical use through multicenter trials.
After launching INTION S in Korea, MedInTech has expanded supply to medical institutions under a distribution agreement with DK Healthcare. It has supplied the product to institutions including the National Fire Service Hospital and Ajou University Hospital, and has recorded initial sales in three overseas markets: Thailand, the Philippines and Mongolia. The company has also commercialized INTION DEEPEYE, AI software that supports detection and classification of abnormal areas in gastric and colon endoscopy images, strengthening its combined hardware and software offering.
Investor views
Yunho Jung, a team lead at Atinum Investment, which co-led the round, said that “MedInTech has laid the groundwork for substantial revenue growth by building a domestic and overseas dealer network.” He said he expects the company’s technological competitiveness and growth potential to be well received in a future initial public offering (IPO).
KB Investment praised MedInTech for the world’s first commercialization of an AI robotic endoscope. It said it focused on the company’s potential to grow into a “global medical AI surgical robot company” that “can innovate even the flexible endoscope surgical robot market, based on technology validated in diagnostic endoscopes.”
Use of funds
MedInTech will spend the funds on two main areas. The first is expanding its AI robotic endoscope scope lineup to meet different clinical settings and clinician needs, and strengthening its existing endoscope business. The second is developing and commercializing surgical robots for internal medicine and surgery, built on the robot control technology it has gained from endoscopes.
By product, the company plans to increase R&D spending, including hiring R&D staff and developing prototypes, and to use the funds across the full commercialization process, including domestic and overseas regulatory approvals and building mass-production capacity. In parallel with a USD 17.3 million (22.8 billion won) multi-ministry advanced medical device R&D program it was selected for in April this year, it will refine its autonomous steering technology and develop ultra-small multi-joint treatment instruments. It aims to speed up development of a next-generation surgical robot platform.
“This Series C funding will be an important opportunity to prepare for the next stage of growth, building on the robotic endoscope technology and commercialization results we have accumulated,” said Chiwon Lee, CEO of MedInTech. “We will expand domestic and overseas supply of our AI robotic endoscope and advance our autonomous steering and precision control technologies to build a next-generation medical robotics platform that extends from diagnosis to treatment and surgery.”
MORE FROM THE POST
- MedInTech Secures 20 billion KRW Series B Investment for Innovative Medical Endoscope
- Heidi Raises $340M for Its AI Care Partner, Now Valued at $900M
- Angle Health Raises $600M at a $2.7B Valuation
- Lyte Raises $165M Series C to Give Robots a Trustworthy View of the World
- Lab Automation Robotics Startup ABLE Labs Raises $8.7M Series A
- AI
- Atinum Investment
- BioHealth
- funding
- HealthCare
- icf
- K2 Investment Partners
- KB Investment
- MedinTech
- mega funding
- physical ai
- robotics
- seriesC
- SL Investment
- Smilegate Investment
- Wooshin Venture Investment
Share
Most Read
- 1
- 2
- 3
- 4
- 5


Leave a Reply